Fabrication of impedimetric sensor based on metallic nanoparticle for the determination of mesna anticancer drug

Electrochemical impedance spectroscopy (EIS) is a highly effective technique for studying the surface of electrodes in great detail. EIS-based electrochemical sensors have been widely reported, which measure the charge transfer resistance (Rct) of redox probes on electrode surfaces to monitor the binding of target molecules. One of the protective drugs against hemorrhagic cystitis caused by oxazaphosphorine chemotherapy drugs such as ifosfamide, cyclophosphamide and trophosphamide is Mesna (sodium salt of 2-mercaptoethanesulfonate). The increase in the use of Mesna due to the high consumption of anti-cancer drugs, the determination of this drug in biological samples is of particular importance. So far, no electrochemical method has been reported to measure Mesna. In this research, a novel impedimetric sensor based on a glassy carbon electrode (GCE) modified with oxidized multiwalled carbon nanotubes (MWCNTs)/gold nanoparticle (AuNPs) (denoted as Au NPs/MWCNTs/GCE) for impedimetric determination of Mesna anticancer drug was developed. The modified electrode materials were characterized by field emission scanning electron microscopy (FESEM), energy dispersive X-ray (EDX), and EIS. The electrochemical behavior of Mesna at the surface of Au NPs/MWCNTs/GCE was studied by an impedimetric method. The detection mechanism of Mesna using the proposed impedimetric sensor relied on the increase in the Rct value of [Fe (CN)6]3-/4- as an electrochemical probe in the presence of Mesna compared to the absence of Mesna as the analyte. Under the optimum condition, which covered two linear dynamic ranges from 0.06 nmol L-1 to 1.0 nmol L-1 and 1.0 nmol L-1 to 130.0 µmol L-1, respectively. The detection limit was 0.02 nmol L-1. Finally, the performance of the proposed sensor was investigated for Mesna electrochemical detection in biological samples.

Biodegradable and Non-Biodegradable Biomaterials and Their Effect on Cell Differentiation

Biomaterials for tissue scaffolds are key components in modern tissue engineering and regenerative medicine. Targeted reconstructive therapies require a proper choice of biomaterial and an adequate choice of cells to be seeded on it. The introduction of stem cells, and the transdifferentiation procedures, into regenerative medicine opened a new era and created new challenges for modern biomaterials. They must not only fulfill the mechanical functions of a scaffold for implanted cells and represent the expected mechanical strength of the artificial tissue, but furthermore, they should also assure their survival and, if possible, affect their desired way of differentiation. This paper aims to review how modern biomaterials, including synthetic (i.e., polylactic acid, polyurethane, polyvinyl alcohol, polyethylene terephthalate, ceramics) and natural (i.e., silk fibroin, decellularized scaffolds), both non-biodegradable and biodegradable, could influence (tissue) stem cells fate, regulate and direct their differentiation into desired target somatic cells.

Enhancing autophagy in Alzheimer's disease through drug repositioning

Alzheimer's disease (AD) is one of the biggest human health threats due to increases in aging of the global population. Unfortunately, drugs for treating AD have been largely ineffective. Interestingly, downregulation of macroautophagy (autophagy) plays an essential role in AD pathogenesis. Therefore, targeting autophagy has drawn considerable attention as a therapeutic approach for the treatment of AD. However, developing new therapeutics is time-consuming and requires huge investments. One of the strategies currently under consideration for many diseases is "drug repositioning" or "drug repurposing". In this comprehensive review, we have provided an overview of the impact of autophagy on AD pathophysiology, reviewed the therapeutics that upregulate autophagy and are currently used in the treatment of other diseases, including cancers, and evaluated their repurposing as a possible treatment option for AD. In addition, we discussed the potential of applying nano-drug delivery to neurodegenerative diseases, such as AD, to overcome the challenge of crossing the blood brain barrier and specifically target molecules/pathways of interest with minimal side effects.

In Situ Growth of Metal-Organic Framework HKUST-1 on Graphene Oxide Nanoribbons with High Electrochemical Sensing Performance in Imatinib Determination

Metal-organic frameworks (MOFs) have been previously investigated as electrode materials for developing electrochemical sensors. They have usually been reported to suffer from poor conductivity and improvement in the conductivity of MOFs is still a great challenge. Here, we reported the fabrication of an electrochemical sensor based on the in situ growth of framework HKUST-1 on conductive graphene oxide nanoribbons (GONRs)-modified glassy carbon electrode (GCE) (HKUST-1/GONRs/GCE). The as-fabricated modified electrode was characterized using field emission scanning electron microscopy, transmission electron microscopy (TEM), high-resolution TEM, Fourier transform infrared, X-ray diffraction, electrochemical impedance spectroscopy, cyclic voltammetry, and Raman spectroscopy. The voltammetric response of HKUST-1/GONRs/GCE toward Imatinib (IMA), as an anticancer drug, is dramatically higher than HKUST-1/GCE because of the synergic effect of the GONRs and HKUST-1 framework. The calibration curve at the HKUST-1/GONRs/GCE for IMA covered two linear dynamic ranges, 0.04-1.0 and 1.0-80 μmol L^-1, with a detection limit of 0.006 μmol L^-1 (6 nmol L^-1). Taking advantage of the conductivity of GONRs and large surface area of HKUST-1, a sensitive modified electrode was developed for the electrochemical determination of IMA. The present method provides an effective strategy to solve the poor conductivity of the MOFs. Finally, the obtained electrochemical performance made this modified electrode promising in the determination of IMA in urine and serum samples.